ClinicalTrials.gg
CompletedNCT05087758Updated Apr 2, 2025

Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

An interventional study of Matrion and Conventional Care Wound Management in Diabetic Foot and Lower Extremity Wound, sponsored by LifeNet Health. Completed at 8 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by LifeNet Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
106th of 322
108 · median 60
Started
2022
with 21 others
No phase
186 of 381
38 open now
Registered
265th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 106th largest by enrollment of the 322 interventional ones that give a count, is one of 22 that started in 2022, is one of 186 with no phase, and was the 265th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.

03

Conditions studied

  • Diabetic Foot
  • Lower Extremity Wound

Browse trials for

Keywords

  • diabetic foot ulcer
  • placental membrane
  • lower extremity wound
  • decellularized placental membrane
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below:

  1. Be male or female, between 21 and 80 years of age at the time of consent
  2. For subjects with a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit
  3. Have a full-thickness wound of the lower extremity
  4. Have a single target ulcer
  5. Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm
  6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:

    • Grade 1: superficial diabetic ulcer including the full skin thickness but not underlying tissue
    • Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess of osteomyelitis
  7. Have an absence of infection based on Infectious Disease Society of America criteria
  8. Have an adequate circulation to the affected lower extremity, defined as at least one these criteria:

    • Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg
    • Ankle-brachial index (ABI) greater than 0.75
    • At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
  9. Have the ability to comply with off-loading (if required for specific wound) and dressing change requirements
  10. Have the ability to understand the requirements of the study, have provided written as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
  11. Have provided written authorization for use and disclosure of protected health information
  12. Have a of greater than 6 months

Exclusion criteria

Exclusion Criteria:

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

  1. Be pregnant or lactating
  2. Have a wound that decreased in size ≥50% between the Screening and Baseline Visits
  3. Have circulating exceeding 12% within 90 days of the Screening Visit
  4. Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening
  5. Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin B Sulfate, and/or Vancomycin
  6. Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase®
  7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit
  8. Need for any additional concomitant dressing material other than the ones approved for this study
  9. Have clinical signs of an infection at the study ulcer site
  10. Have the inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast)
  11. Have a known or suspected disease of the immune system
  12. Have an active or untreated or active, uncontrolled connective tissue disease
  13. Had a treatment with or chemotherapeutic agents, radiotherapy or systemic less than 30 days before the baseline visit
  14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement
  15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit
  16. Have serum , alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening
  17. Have evidence of active Charcot disease
  18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
  19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
  20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Matrion decellularized placental membrane

    Matrion placental membrane graft will be use to treat subjects diagnosed with a diabetic foot ulcer.

    Other: Matrion

  • Active comparator
    Conventional Care Wound Management

    Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diabetic foot ulcer diagnosis.

    Other: Conventional Care Wound Management

Interventions

  • OtherMatrion

    Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers

  • OtherConventional Care Wound Management

    Advanced wound care with debridement and dressings

06

What researchers measure

Primary outcomes

  1. Wound Healing

    Proportion of chronic DFUs that have achieved complete wound closure

    Time frame: 12 weeks

Secondary outcomes

  1. Speed of Wound Closure

    Time to wound closure measured from the baseline visit to the termination visit

    Time frame: 12 weeks

  2. Wound Area

    Change in wound area over time

    Time frame: 12 weeks

  3. Infection

    Rate of wound infection

    Time frame: 12 weeks

  4. Reoccurrence

    Rate of reoccurrence of wound post treatment

    Time frame: 6 months post termination visit

  5. Grafts Used

    Average number of Matrion grafts used per subject

    Time frame: 12 weeks

  6. Incidence of Treatment Emergent Adverse Events

    Collection of adverse events, including changes in vital signs, ABI, and physical exams

    Time frame: 12 weeks

07

Study locations

8 sites
  • Compass Medical Research Center, LLC
    Tucson, Arizona 85715, United States
  • Center for Clinical Research, INC
    Carmichael, California 95608, United States
  • Limb Preservation Platform, INC
    Fresno, California 93710, United States
  • ILD Research Center
    San Diego, California 92130, United States
  • Center for Clinical Research, INC
    San Francisco, California 94115, United States
  • Doctors Research Network
    Miami, Florida 33143, United States
  • Albuquerque Associated Podiatrists
    Albuquerque, New Mexico 87111, United States
  • Purvis-Moyer Foot and Ankle Center
    Rocky Mount, North Carolina 27804, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2024, 33 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 33 months is above that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2021
First posted
Oct 21, 2021
StartActual
Mar 1, 2022
Primary completionActual
Dec 31, 2024
CompletionActual
Feb 28, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05087758
Lead sponsor
LifeNet Health
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Mar 1, 2022
Primary completion
Dec 31, 2024
Completion
Feb 28, 2025
Last update
Apr 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion